KRAS and non-small cell lung carcinoma: Regarding SMARCA4/KRAS co-mutations, all seven treatment analyses (four with ICIs, two with non-ICIs, and one with KRAS G12C inhibitors) indicated that co-mutated SMARCA4/KRAS NSCLC patients consistently had significantly worse OS than SMARCA4 WT/KRAS-mutated cohorts [8,21,22,34,35,36,37].